Cargando…
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
BACKGROUND: Many methodologies have been used in research to identify the “intrinsic” subtypes of breast cancer commonly known as Luminal A, Luminal B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often used for gene expression-based subtyping; however, surrogate subtyping using pane...
Autores principales: | Bastien, Roy RL, Rodríguez-Lescure, Álvaro, Ebbert, Mark TW, Prat, Aleix, Munárriz, Blanca, Rowe, Leslie, Miller, Patricia, Ruiz-Borrego, Manuel, Anderson, Daniel, Lyons, Bradley, Álvarez, Isabel, Dowell, Tracy, Wall, David, Seguí, Miguel Ángel, Barley, Lee, Boucher, Kenneth M, Alba, Emilio, Pappas, Lisa, Davis, Carole A, Aranda, Ignacio, Fauron, Christiane, Stijleman, Inge J, Palacios, José, Antón, Antonio, Carrasco, Eva, Caballero, Rosalía, Ellis, Matthew J, Nielsen, Torsten O, Perou, Charles M, Astill, Mark, Bernard, Philip S, Martín, Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487945/ https://www.ncbi.nlm.nih.gov/pubmed/23035882 http://dx.doi.org/10.1186/1755-8794-5-44 |
Ejemplares similares
-
Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans
por: Ebbert, Mark TW, et al.
Publicado: (2011) -
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
por: Martín, Miguel, et al.
Publicado: (2013) -
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
por: Martin, Miguel, et al.
Publicado: (2016) -
PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer
por: Prat, A., et al.
Publicado: (2012) -
Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series
por: Picornell, A. C., et al.
Publicado: (2019)